In summary, our study may be used to determine the possible molecular mechanisms of DCR3 in osteoclastogenesis and may reveal DCR3 as a potential therapeutic agent that is beneficial for the treatment of inflammatory bone disorder diseases, such as gingivitis, which are involved in IL-1α/IL-1ra imbalances. The gene discussed is TNFRSF6B; the disease is gingivitis.